Literature DB >> 11171123

Transcription factor AP-4 is a ligand for immunoglobulin-kappa promoter E-box elements.

A Aranburu1, R Carlsson, C Persson, T Leanderson.   

Abstract

Immunoglobulin (Ig)-kappa promoters from humans and mice share conserved sequences. The octamer element is common to all Ig promoters and pivotal for their function. However, other conserved sequence motifs, that differ between Ig variable gene families, are required for normal promoter function. These conserved motifs do not stimulate transcription in the absence of an octamer. One example is an E-box of the E47/E12 type (5'-CAGCTG-3'), which is found in all promoters of the human and murine Ig-kappa gene subgroups/families, with the exception of subgroups II and VI and their related murine families. In the present study we show that the ubiquitously expressed transcription factor AP-4, and not E47, interacts specifically with the kappa promoter E-boxes when tested in electrophoretic mobility-shift assays using nuclear extracts derived from human and murine B-cell lines. Furthermore, AP-4, unlike E47, did not act as a transactivator, which is in agreement with previous studies on intact kappa promoters, showing that transcription is absent when the octamer element has been mutated. Based on these data, and the conservation of the 5'-CAGCTG-3' motif among human and murine kappa promoters, we propose that AP-4 is the major ligand for Ig-kappa promoter E-boxes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11171123      PMCID: PMC1221672          DOI: 10.1042/0264-6021:3540431

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  35 in total

1.  Transcription factor AP-4 contains multiple dimerization domains that regulate dimer specificity.

Authors:  Y F Hu; B Lüscher; A Admon; N Mermod; R Tjian
Journal:  Genes Dev       Date:  1990-10       Impact factor: 11.361

2.  Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection.

Authors:  T K Blackwell; H Weintraub
Journal:  Science       Date:  1990-11-23       Impact factor: 47.728

3.  A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins.

Authors:  C Murre; P S McCaw; D Baltimore
Journal:  Cell       Date:  1989-03-10       Impact factor: 41.582

4.  Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells.

Authors:  E Schreiber; P Matthias; M M Müller; W Schaffner
Journal:  Nucleic Acids Res       Date:  1989-08-11       Impact factor: 16.971

5.  An octamer oligonucleotide upstream of a TATA motif is sufficient for lymphoid-specific promoter activity.

Authors:  T Wirth; L Staudt; D Baltimore
Journal:  Nature       Date:  1987 Sep 10-16       Impact factor: 49.962

6.  Two regulatory elements for immunoglobulin kappa light chain gene expression.

Authors:  Y Bergman; D Rice; R Grosschedl; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

7.  Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro.

Authors:  N Mermod; T J Williams; R Tjian
Journal:  Nature       Date:  1988-04-07       Impact factor: 49.962

8.  A novel upstream element compensates for an ineffectual octamer motif in an immunoglobulin V kappa promoter.

Authors:  M L Atchison; V Delmas; R P Perry
Journal:  EMBO J       Date:  1990-10       Impact factor: 11.598

9.  Proteins bound at adjacent DNA elements act synergistically to regulate human proenkephalin cAMP inducible transcription.

Authors:  M Comb; N Mermod; S E Hyman; J Pearlberg; M E Ross; H M Goodman
Journal:  EMBO J       Date:  1988-12-01       Impact factor: 11.598

10.  Mouse Vk gene classification by nucleic acid sequence similarity.

Authors:  R Strohal; A Helmberg; G Kroemer; R Kofler
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

View more
  7 in total

1.  Association of SNP in exon 1 of HBS1L with hemoglobin F level in beta0-thalassemia/hemoglobin E.

Authors:  Riyaz A Pandit; Saovaros Svasti; Orapan Sripichai; Thongperm Munkongdee; Kanokporn Triwitayakorn; Pranee Winichagoon; Suthat Fucharoen; Chayanon Peerapittayamongkol
Journal:  Int J Hematol       Date:  2008-10-07       Impact factor: 2.490

2.  Long-range interactions between three transcriptional enhancers, active Vkappa gene promoters, and a 3' boundary sequence spanning 46 kilobases.

Authors:  Zhe Liu; William T Garrard
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

3.  Functional analysis of a promoter variant of the gene encoding the interferon-gamma receptor chain I.

Authors:  Simone Jüliger; Martina Bongartz; Adrian J F Luty; Peter G Kremsner; Jürgen F J Kun
Journal:  Immunogenetics       Date:  2002-12-14       Impact factor: 2.846

4.  Assembly and analysis of the mouse immunoglobulin kappa gene sequence.

Authors:  Katherine M Brekke; William T Garrard
Journal:  Immunogenetics       Date:  2004-09-18       Impact factor: 2.846

5.  Complementary quantitative proteomics reveals that transcription factor AP-4 mediates E-box-dependent complex formation for transcriptional repression of HDM2.

Authors:  Wei-Chi Ku; Sung-Kay Chiu; Yi-Ju Chen; Hsin-Hung Huang; Wen-Guey Wu; Yu-Ju Chen
Journal:  Mol Cell Proteomics       Date:  2009-06-07       Impact factor: 5.911

6.  Down-regulation of AP-4 inhibits proliferation, induces cell cycle arrest and promotes apoptosis in human gastric cancer cells.

Authors:  Xinghua Liu; Bo Zhang; Yan Guo; Qi Liang; Changyao Wu; Lei Wu; Kaixiong Tao; Guobin Wang; Jianying Chen
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

7.  TranscriptomeBrowser 3.0: introducing a new compendium of molecular interactions and a new visualization tool for the study of gene regulatory networks.

Authors:  Cyrille Lepoivre; Aurélie Bergon; Fabrice Lopez; Narayanan B Perumal; Catherine Nguyen; Jean Imbert; Denis Puthier
Journal:  BMC Bioinformatics       Date:  2012-01-31       Impact factor: 3.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.